Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide for weight loss is taken once a week as a subcutaneous injection using the Mounjaro KwikPen, starting at 2.5 mg and titrated upward by a prescriber over several months. It is a prescription-only medicine; a clinician assesses whether it is suitable for you before any treatment begins. Most people find the mechanics straightforward once they have tried their first injection, yet a handful of persistent myths about technique, dose timing and storage can get in the way from the start. This page works through those misconceptions and replaces them with the facts.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Many people start tirzepatide convinced that injection technique must be highly precise, the right angle to the millimetre, a specific region of the abdomen that is somehow more effective than another. In practice, the licensed injection sites are broad: the abdomen (avoiding the navel area), the front of the thigh, and the outer upper arm. Any of these works. What matters far more than pinpoint location is rotation, moving to a different spot within whichever site you use each week. Injecting into the same small area repeatedly causes a build-up of scar-like tissue under the skin that can slow absorption.
Before you inject, you do not need to pinch the skin unless you have very little subcutaneous fat in that area, and you do not need to rub the site afterwards. If you want a full walkthrough of the device itself, our guide on how to use the tirzepatide pen covers each step in detail, including the correct angle, how to hold the pen in place until the injection is complete, and what the click and indicator window change tell you. Then dispose of your used pen in a proper sharps container; a 1-litre sharps container keeps disposal safe and legal at home.
A question our prescribers hear regularly: does it hurt? For most people, far less than expected. The needle is very fine. Cold medicine from the fridge can sting, which is one practical reason to let the pen sit out briefly before use, though always within the time window stated in your leaflet, not longer.
Once-weekly dosing sounds simple, and it is, but the question of when on your chosen day trips people up. Tirzepatide can be injected at any time of day, with or without food. The important thing is consistency: the same day each week. If you learn more about building a weekly routine around tirzepatide, you will find that most people attach it to something fixed: a Sunday morning ritual, a standing reminder on a phone, or the moment they reach into the fridge door next to where the pen lives.
If your injection day needs to shift by a day or two in a given week, that is generally manageable because the medicine has a long half-life. However, the specifics of how to handle a delayed or missed dose are for your prescriber and the Patient Information Leaflet to advise on, not content like this. If you are unsure in the moment, contact your clinical team rather than guessing.
Alcohol swabs are sometimes used to clean the injection site beforehand; sterile alcohol swabs kept with your pen make this straightforward. Again, your leaflet and prescriber will confirm whether this step applies to your individual routine.
Tirzepatide is available in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. Treatment begins at 2.5 mg. Many people read this and assume something has gone wrong when they do not see significant change in the first four weeks; the starter dose's job is to prepare your digestive system, not to drive the main therapeutic effect. Appetite suppression becomes more pronounced as the dose climbs, guided by your prescriber's clinical judgement.
The NHS tirzepatide medicines page explains the mechanism clearly: tirzepatide activates both GIP and GLP-1 receptors involved in appetite regulation and blood-sugar control, slowing how quickly the stomach empties. This dual-receptor action is what makes it distinct among licensed weight-loss medicines in the UK. In the SURMOUNT-1 clinical trial, average body-weight reduction reached around 20–21% at the 15 mg dose over 72 weeks, a result detailed in the published trial paper in the New England Journal of Medicine. Those figures came alongside a reduced-calorie diet and increased physical activity, which remain part of the licensed approach, and our guide on how to use Mounjaro for weight loss explains how diet and activity fit around the treatment in practice.
For a broader look at what the pen itself contains and how it is constructed, the guide to the tirzepatide KwikPen covers the device in more detail. And if you want to compare tirzepatide with other licensed weight-loss injections side by side, the weight-loss injections overview sets out the current options.
The most common side effects while using tirzepatide are gastrointestinal: nausea, loose stools, constipation, indigestion, burping, and sometimes fatigue or headache. These tend to be most noticeable in the days following a new or increased dose, then ease. Eating smaller portions, avoiding very fatty meals, and staying well hydrated all help, and slowing down dose increases is sometimes the right clinical move, which is a conversation for your prescriber.
Two things need prompt medical attention rather than a watch-and-wait approach. First: severe, persistent abdominal pain that spreads toward the back, particularly with vomiting, this pattern can indicate pancreatitis, and in January 2026 the MHRA issued a specific Drug Safety Update flagging this risk for GLP-1 medicines. Second: signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing). Neither is common, but both are serious. You can report suspected side effects directly via the MHRA Yellow Card scheme.
Women using oral contraceptives should be aware that tirzepatide slows gastric emptying in a way that may reduce pill absorption; NHS guidance recommends adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase. This is worth raising at your initial consultation. Pregnancy, breastfeeding and treatment aimed at conceiving are all situations where tirzepatide is not recommended, and it is not licensed for anyone under 18.
If you are considering tirzepatide and want to understand what private treatment involves (including how pricing works across providers) the Mounjaro price comparison guide covers the market honestly. When you are ready to speak to a prescriber, you can start your free consultation and have your answers reviewed the same day by a GPhC-registered Independent Prescriber at our pharmacy.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.